<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088137</url>
  </required_header>
  <id_info>
    <org_study_id>FSG-03-01</org_study_id>
    <nct_id>NCT03088137</nct_id>
  </id_info>
  <brief_title>Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment</brief_title>
  <official_title>Multicentre Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVFarma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BridgePharm LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlobalPharma LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IVFarma LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show equivalence with regard to the number of oocytes
      retrieved between follitropin alfa (pen-injectors) Primapur® and Gonal-f® in woman undergoing
      IVF/ICSI
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Actual">August 17, 2018</completion_date>
  <primary_completion_date type="Actual">August 17, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oocytes (Intention-to-Treat, ITT)</measure>
    <time_frame>From date of randomization up to 18 days</time_frame>
    <description>The total number of retrieved oocytes at the day of ovum pick-up. No more than 37 hours from the introduction of the trigger of ovulation (hCG or GnRH-agonist). The equivalence in the number of retrieved oocytes was tested using a predetermined equivalence margin of +/- 3.4 oocytes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Follicles With Size ≥ 16 mm</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
    <description>The number of follicles 16 mm or over in diameter at the day of hCG (or GnRH-agonist) administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mature Oocytes</measure>
    <time_frame>From date of randomization up to 18 days</time_frame>
    <description>The number of mature oocytes (MII stage of development)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilised Oocytes</measure>
    <time_frame>From date of randomization up to 19 days</time_frame>
    <description>The number of fertilised oocytes with the presence of two pronuclei: 2PN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Embryo Transfer</measure>
    <time_frame>From date of randomization up to 25 days</time_frame>
    <description>The number of patients (and percentage) with embryo transfers on days 3 and 5 after ovum pick-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Dose of Follitropin Alfa</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
    <description>The total dose of the follitropin alfa administrated during the ovarian hyperstimulation protocol (measured in International Units - IU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Follitropin Alfa Treatment</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
    <description>The duration of ovarian hyperstimulation protocol (at the day of trigger of ovulation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Follitropin Alfa Dose Correction</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
    <description>The number of dose adjustments during the ovarian hyperstimulation protocol (increment 25-50 IU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Cycle Cancellation</measure>
    <time_frame>From date of randomization up to 16 days</time_frame>
    <description>The number of the ovarian hyperstimulation protocol cancellation (at the day of trigger of ovulation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of No-responders</measure>
    <time_frame>From date of randomization up to 8 days</time_frame>
    <description>The number of patients with no response to follitropin alfa treatment (absence of growing follicles, no any oocytes obtained at the day of ovum pick-up)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Serum hCG More Than 25 IU/l</measure>
    <time_frame>From date of randomization up to 42 days</time_frame>
    <description>Biochemical pregnancy test: serum hCG more than 25 IU/l (days 12-17 after embryo transfer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With the Evidence for Clinical Pregnancy</measure>
    <time_frame>The 10th week after embryo transfer</time_frame>
    <description>Confirmation of clinical pregnancy: ultrasound detection of intrauterine gestational sac and heart activity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Primapur (Follitropin alfa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-f (Follitropin alfa)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin alfa (Gonal-f)</intervention_name>
    <description>Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
    <arm_group_label>Gonal-f (Follitropin alfa)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin alfa (Primapur)</intervention_name>
    <description>Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
    <arm_group_label>Primapur (Follitropin alfa)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infertility due to tubal factor and/or male factor

          -  Age between 20 and 35 years with regular menstrual cycles of 21-35 days

          -  First or second cycle in the present series of ART

          -  BMI (body mass index) ≥ 18 ≤ 30 kg/m2

          -  Basal FSH (follicle stimulating hormone) &lt; 10 IU/L (cycle day 2-5)

          -  E2 (estradiol) levels &lt; 50pg/mL (cycle day 2)

          -  AMH (anti-mullerian hormone) ≥ 1.0 ng/ml

          -  Antral follicle ≥ 4 to ≤ 15 follicles (both ovaries)

          -  Presence of both ovaries and normal uterine cavity

          -  Informed consent

        Exclusion Criteria:

          -  Presence of pregnancy

          -  Hypersensitivity to follitropin alfa

          -  Ovarian cysts

          -  History of ≥2 succeeding ART (assisted reproductive technology) cycles IVF (in vitro
             fertilization) and/or ICSI (Intracytoplasmic sperm injection) before the study cycle

          -  Previous history of severe ovarian hyperstimulation syndrome

          -  Presence of polycystic ovaries (PCO)

          -  Presence of endometriosis and hydrosalpinx

          -  Presence of uterine disorders

          -  History of poor (&lt; 4 oocytes) or hyper (&gt; 25 oocytes) responses to FSH treatment at
             dose 150 IU and GnRH-antagonist (gonadotropin-releasing hormone) protocol

          -  Premature ovarian failure

          -  Ectopic pregnancy (3 month before the study cycle)

          -  Presence of clinically significant systemic disease

          -  Presence of chronic cardiovascular, hepatic, renal or pulmonary disease

          -  Presence of endocrine disorder

          -  Neoplasia

          -  Male infertility without mobile spermatozoa in the ejaculate, that need MESA
             (Microsurgical epididymal sperm aspiration)/TESE (testicular sperm extraction)/TESA
             (testicular sperm aspiration)

          -  Smoking &gt; 10 cigarettes/day

          -  Narcomania, alcoholism

          -  Planned PGS (preimplantation genetic screeneing) /PGD (preimplantation genetic
             diagnosis)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Hospital Lapino</name>
      <address>
        <city>Moscow Oblast</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AltraVita IVF clinic</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal Medical Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1093/humrep/34.Supplement_1.1</url>
    <description>Abstracts of the 35th Annual Meeting of the ESHRE, Vienna, Austria 24 to 26 June 2019</description>
  </link>
  <link>
    <url>https://doi.org/10.1016/j.ejogrb.2019.07.032</url>
    <description>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology Volume 241, October 2019, Pages 6-12</description>
  </link>
  <results_reference>
    <citation>M. Polzikov, Z. Barakhoeva, S. Yakovenko, M. Ovchinnikova, L.Vovk, Y. Fetisova. A multicenter, randomized study comparing the efficacy of follitropin alpha biosimilar and the original follitropin alpha. Abstracts of the 35th Annual Meeting of the ESHRE, Vienna, Austria 24 to 26 June 2019 (abstract P-649), Human Reproduction, 2019; Vol. 34, Suppl. 1, p. i439.</citation>
  </results_reference>
  <results_reference>
    <citation>Barakhoeva Z, Vovk L, Fetisova Y, Marilova N, Ovchinnikova M, Tischenko M, Scherbatyuk Y, Kolotovkina A, Miskun A, Kasyanova G, Teterina T, Zorina I, Belousova N, Morozova E, Yakovenko S, Apryshko V, Sichinava L, Shalinа R, Polzikov M. A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha. Eur J Obstet Gynecol Reprod Biol. 2019 Oct;241:6-12. doi: 10.1016/j.ejogrb.2019.07.032. Epub 2019 Jul 26.</citation>
    <PMID>31400644</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <results_first_submitted>October 13, 2018</results_first_submitted>
  <results_first_submitted_qc>June 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2019</results_first_posted>
  <last_update_submitted>August 11, 2019</last_update_submitted>
  <last_update_submitted_qc>August 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in vitro fertilization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03088137/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled at 3 In Vitro Fertilisation (IVF) centers in Russian Federation from 08.02.2017 – 17.08.2018.</recruitment_details>
      <pre_assignment_details>Of 118 participants: 8 were reported as screening failures prior the group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Primapur (Follitropin Alfa)</title>
          <description>Follitropin alfa (Primapur): Subcutaneous injection (pen-injector), fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
        </group>
        <group group_id="P2">
          <title>Gonal-f (Follitropin Alfa)</title>
          <description>Follitropin alfa (Gonal-f): Subcutaneous injection (pen-injector), fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Primapur (Follitropin Alfa)</title>
          <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
        </group>
        <group group_id="B2">
          <title>Gonal-f (Follitropin Alfa)</title>
          <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Mean (Standard Deviation)</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="2.68"/>
                    <measurement group_id="B2" value="30.0" spread="2.71"/>
                    <measurement group_id="B3" value="30.65" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>kg/m2</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.0" spread="2.69"/>
                    <measurement group_id="B2" value="22.3" spread="3.06"/>
                    <measurement group_id="B3" value="22.15" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of infertility</title>
          <description>month</description>
          <units>month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" spread="32.4"/>
                    <measurement group_id="B2" value="36.9" spread="26.6"/>
                    <measurement group_id="B3" value="41.65" spread="28.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antral follicle</title>
          <description>Mean (Standard Deviation)</description>
          <units>Number of antral follicles</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" spread="3.2"/>
                    <measurement group_id="B2" value="12.4" spread="2.4"/>
                    <measurement group_id="B3" value="11.80" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-mullerian hormone (AMH)</title>
          <description>Mean (Standard deviation)</description>
          <units>ng per ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.57" spread="2.96"/>
                    <measurement group_id="B2" value="5.47" spread="3.82"/>
                    <measurement group_id="B3" value="5.02" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Follicle stimulating hormone (FSH)</title>
          <description>IU per l</description>
          <units>IU/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.46" spread="1.86"/>
                    <measurement group_id="B2" value="6.76" spread="1.89"/>
                    <measurement group_id="B3" value="6.61" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estradiol</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.87" spread="12.67"/>
                    <measurement group_id="B2" value="33.82" spread="12.45"/>
                    <measurement group_id="B3" value="34.85" spread="12.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cause of infertility</title>
          <description>Patients with the determined cause of infertility</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Tubal factor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male factor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Tubal and male factors</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Oocytes (Intention-to-Treat, ITT)</title>
        <description>The total number of retrieved oocytes at the day of ovum pick-up. No more than 37 hours from the introduction of the trigger of ovulation (hCG or GnRH-agonist). The equivalence in the number of retrieved oocytes was tested using a predetermined equivalence margin of +/- 3.4 oocytes.</description>
        <time_frame>From date of randomization up to 18 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Oocytes (Intention-to-Treat, ITT)</title>
          <description>The total number of retrieved oocytes at the day of ovum pick-up. No more than 37 hours from the introduction of the trigger of ovulation (hCG or GnRH-agonist). The equivalence in the number of retrieved oocytes was tested using a predetermined equivalence margin of +/- 3.4 oocytes.</description>
          <population>Intention-to-Treat</population>
          <units>Number of retrieved oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.16" spread="7.28"/>
                    <measurement group_id="O2" value="11.62" spread="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Study power of at least 80% at a significance level (alpha error) 5% and a pre-determined clinical equivalence margin of +/- 3.4 oocytes for the relevant population.</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.546</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.297</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.026</ci_lower_limit>
            <ci_upper_limit>3.116</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Follicles With Size ≥ 16 mm</title>
        <description>The number of follicles 16 mm or over in diameter at the day of hCG (or GnRH-agonist) administration</description>
        <time_frame>From date of randomization up to 16 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Follicles With Size ≥ 16 mm</title>
          <description>The number of follicles 16 mm or over in diameter at the day of hCG (or GnRH-agonist) administration</description>
          <population>Intention-to-Treat</population>
          <units>Number of follicles</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.09" spread="6.159"/>
                    <measurement group_id="O2" value="11.38" spread="4.965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.806</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.709</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.067</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.405</ci_lower_limit>
            <ci_upper_limit>2.824</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mature Oocytes</title>
        <description>The number of mature oocytes (MII stage of development)</description>
        <time_frame>From date of randomization up to 18 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Mature Oocytes</title>
          <description>The number of mature oocytes (MII stage of development)</description>
          <population>Intention-to-Treat</population>
          <units>Number of mature oocytes (MII stage)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.64" spread="6.270"/>
                    <measurement group_id="O2" value="9.86" spread="5.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.617</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.218</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.129</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.455</ci_lower_limit>
            <ci_upper_limit>2.019</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fertilised Oocytes</title>
        <description>The number of fertilised oocytes with the presence of two pronuclei: 2PN</description>
        <time_frame>From date of randomization up to 19 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Fertilised Oocytes</title>
          <description>The number of fertilised oocytes with the presence of two pronuclei: 2PN</description>
          <population>Intention-to-Treat</population>
          <units>Number of oocytes with 2PN</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.127" spread="6.608"/>
                    <measurement group_id="O2" value="8.764" spread="5.850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.445</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.636</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.190</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.995</ci_lower_limit>
            <ci_upper_limit>1.723</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Embryo Transfer</title>
        <description>The number of patients (and percentage) with embryo transfers on days 3 and 5 after ovum pick-up</description>
        <time_frame>From date of randomization up to 25 days</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Embryo Transfer</title>
          <description>The number of patients (and percentage) with embryo transfers on days 3 and 5 after ovum pick-up</description>
          <population>Per Protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Embryo transfer on day 3 (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Embryo transfer on day 5 (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.623</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Dose of Follitropin Alfa</title>
        <description>The total dose of the follitropin alfa administrated during the ovarian hyperstimulation protocol (measured in International Units - IU)</description>
        <time_frame>From date of randomization up to 16 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dose of Follitropin Alfa</title>
          <description>The total dose of the follitropin alfa administrated during the ovarian hyperstimulation protocol (measured in International Units - IU)</description>
          <population>Intention-to-Treat</population>
          <units>Total dose (IU)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1532.7" spread="267.2"/>
                    <measurement group_id="O2" value="1517.9" spread="255.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.488</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.9</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>49.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-83.9</ci_lower_limit>
            <ci_upper_limit>113.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Follitropin Alfa Treatment</title>
        <description>The duration of ovarian hyperstimulation protocol (at the day of trigger of ovulation)</description>
        <time_frame>From date of randomization up to 16 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Follitropin Alfa Treatment</title>
          <description>The duration of ovarian hyperstimulation protocol (at the day of trigger of ovulation)</description>
          <population>Intention-to-Treat</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.745" spread="1.075"/>
                    <measurement group_id="O2" value="9.727" spread="1.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.629</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.018</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.201</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.379</ci_lower_limit>
            <ci_upper_limit>0.416</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Follitropin Alfa Dose Correction</title>
        <description>The number of dose adjustments during the ovarian hyperstimulation protocol (increment 25-50 IU)</description>
        <time_frame>From date of randomization up to 16 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Follitropin Alfa Dose Correction</title>
          <description>The number of dose adjustments during the ovarian hyperstimulation protocol (increment 25-50 IU)</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.644</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Cycle Cancellation</title>
        <description>The number of the ovarian hyperstimulation protocol cancellation (at the day of trigger of ovulation)</description>
        <time_frame>From date of randomization up to 16 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Cycle Cancellation</title>
          <description>The number of the ovarian hyperstimulation protocol cancellation (at the day of trigger of ovulation)</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of No-responders</title>
        <description>The number of patients with no response to follitropin alfa treatment (absence of growing follicles, no any oocytes obtained at the day of ovum pick-up)</description>
        <time_frame>From date of randomization up to 8 days</time_frame>
        <population>Intention-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of No-responders</title>
          <description>The number of patients with no response to follitropin alfa treatment (absence of growing follicles, no any oocytes obtained at the day of ovum pick-up)</description>
          <population>Intention-to-Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Serum hCG More Than 25 IU/l</title>
        <description>Biochemical pregnancy test: serum hCG more than 25 IU/l (days 12-17 after embryo transfer)</description>
        <time_frame>From date of randomization up to 42 days</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Serum hCG More Than 25 IU/l</title>
          <description>Biochemical pregnancy test: serum hCG more than 25 IU/l (days 12-17 after embryo transfer)</description>
          <population>Per Protocol</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" lower_limit="21.4" upper_limit="48.0"/>
                    <measurement group_id="O2" value="36.7" lower_limit="23.2" upper_limit="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>95% confidence intervals (CIs) of point estimates were calculated using the exact binomial distribution (Clopper-Pearson method) for proportions.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.833</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.0</ci_lower_limit>
            <ci_upper_limit>17.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With the Evidence for Clinical Pregnancy</title>
        <description>Confirmation of clinical pregnancy: ultrasound detection of intrauterine gestational sac and heart activity</description>
        <time_frame>The 10th week after embryo transfer</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Primapur (Follitropin Alfa)</title>
            <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
          <group group_id="O2">
            <title>Gonal-f (Follitropin Alfa)</title>
            <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With the Evidence for Clinical Pregnancy</title>
          <description>Confirmation of clinical pregnancy: ultrasound detection of intrauterine gestational sac and heart activity</description>
          <population>Per Protocol</population>
          <units>Percentage of patients (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="14.1" upper_limit="38.9"/>
                    <measurement group_id="O2" value="32.7" lower_limit="19.6" upper_limit="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>95% confidence intervals (CIs) of point estimates were calculated using the exact binomial distribution (Clopper-Pearson method) for proportions.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.507</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.3</ci_lower_limit>
            <ci_upper_limit>11.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 6 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Primapur (Follitropin Alfa)</title>
          <description>Follitropin alfa (Primapur): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
        </group>
        <group group_id="E2">
          <title>Gonal-f (Follitropin Alfa)</title>
          <description>Follitropin alfa (Gonal-f): Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Iatrogenic injury</sub_title>
                <description>iatrogenic bladder injury during transvaginal ovarian puncturing</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Threatened miscarriage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian hyperstymulation syndrome</sub_title>
                <description>Patients with positive pregnancy test</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sternum pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Laboratory investigations</sub_title>
                <description>Erythrocyte level increase in urine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Spontaneous miscarriage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Early Toxicosis During Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Abnormal vaginal bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Spotting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lower abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menses</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Ovarian hyperstimulation syndrome</sub_title>
                <description>Patients with negative pregnancy test</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Decrease in breast sensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lower abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pains in the lower abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Abnormal vaginal bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Spotting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mikhail Polzikov (PhD)</name_or_title>
      <organization>IVFarma LLC</organization>
      <phone>+74996455342 ext 1</phone>
      <email>mikhail.polzikov@ivfarma.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

